Phase 2b Controlled Trial of M72/AS01E Vaccine to Prevent Tuberculosis.

Olivier Van Der MeerenMark HatherillVidelis NdubaRobert J WilkinsonMonde MuyoyetaElana Van BrakelHelen M AylesGerman HenostrozaFriedrich ThienemannThomas J ScribaAndreas DiaconGretta L BlatnerMarie-Ange DemoitiéMichele TamerisMookho MalahlehaJames C InnesElizabeth HellströmNeil MartinsonTina SinghElaine J AkiteAisha Khatoon AzamAnne BollaertsAnn M GinsbergThomas G EvansPaul GillardDereck R Tait

Published in: The New England journal of medicine (2018)

M72/AS01E provided 54.0% protection for M. tuberculosis-infected adults against active pulmonary tuberculosis disease, without evident safety concerns. (Funded by GlaxoSmithKline Biologicals and Aeras; ClinicalTrials.gov number, NCT01755598 .).

Keyphrases

pulmonary tuberculosis
mycobacterium tuberculosis
open label
study protocol
emergency department
randomized controlled trial
double blind